Insider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Sells 10,500 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zevra Therapeutics Stock Performance

ZVRA opened at $8.07 on Monday. The stock has a market cap of $430.74 million, a P/E ratio of -4.10 and a beta of 2.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock’s 50 day simple moving average is $8.22 and its 200 day simple moving average is $8.07. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76.

Analysts Set New Price Targets

Several analysts have commented on ZVRA shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Finally, Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $21.57.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp grew its holdings in shares of Zevra Therapeutics by 22.9% in the 4th quarter. Northern Trust Corp now owns 435,972 shares of the company’s stock worth $3,636,000 after acquiring an additional 81,252 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Zevra Therapeutics in the 4th quarter worth approximately $716,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock worth $172,000 after acquiring an additional 6,966 shares during the period. Finally, Diadema Partners LP acquired a new stake in Zevra Therapeutics during the 4th quarter valued at $351,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.